CRBU (Caribou Biosciences, Inc. Common Stock) Stock Analysis - News
Caribou Biosciences, Inc. Common Stock (CRBU) is a publicly traded Healthcare sector company. As of May 21, 2026, CRBU trades at $2.01 with a market cap of $205.30M and a P/E ratio of -1.24. CRBU moved +0.76% today. Year to date, CRBU is +24.22%; over the trailing twelve months it is +81.82%. Its 52-week range spans $0.66 to $3.54. Analyst consensus is strong buy with an average price target of $9.00. Rallies surfaces CRBU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CRBU news today?
Caribou to Present 84-Patient Vispa-cel Durability, 48-Patient CB-011 Follow-Up at EHA: Caribou Biosciences will present long-term durability data for vispa-cel from its ANTLER phase 1 trial at the EHA meeting June 12, following treatment of 84 patients and identification of 80×10^6 CAR-T cells as RP2D. A second presentation on June 14 covers extended follow-up in 48-patient CaMMouflage phase 1 CB-011 trial.
Caribou to Present 84-Patient Vispa-cel Durability, 48-Patient CB-011 Follow-Up at EHA: Caribou Biosciences will present long-term durability data for vispa-cel from its ANTLER phase 1 trial at the EHA meeting June 12, following treatment of 84 patients and identification of 80×10^6 CAR-T cells as RP2D. A second presentation on June 14 covers extended follow-up in 48-patient CaMMouflage phase 1 CB-011 trial.
Does Rallies summarize CRBU news?
Yes. Rallies summarizes CRBU news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CRBU research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CRBU. It does not provide personalized investment advice.
